Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.

@article{Tefferi2014PrimaryM2,
  title={Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.},
  author={Ayalew Tefferi},
  journal={American journal of hematology},
  year={2014},
  volume={89 9},
  pages={915-25}
}
DISEASE OVERVIEW Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by stem cell-derived clonal myeloproliferation, abnormal cytokine expression, bone marrow fibrosis, anemia, splenomegaly, extramedullary hematopoiesis (EMH), constitutional symptoms, cachexia, leukemic progression, and shortened survival. DIAGNOSIS DIAGNOSIS is based on bone marrow morphology. The presence of JAK2, CALR, or MPL mutation is supportive but not essential for diagnosis; approximately 90… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 43 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 105 references

Outcome of transplantation for myelofibrosis.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation • 2010
View 3 Excerpts
Highly Influenced

A dynamic prognostic model to predict ANNUAL CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES doi:10.1002/ajh.23703

F Passamonti, F Cervantes, AM Vannucchi
American Journal of Hematology, • 2014
View 1 Excerpt

U 2 AF 1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK 2 V 617 F and normal karyotype

A Tefferi, CM Finke, TL Lasho
Leukemia • 2014

Similar Papers

Loading similar papers…